OCS-01, an eye drop developed by Oculis Holding and currently under phase 3 trials for diabetic ... The injection is invasive ...

Alcon Inc.’s ALC growth in the third quarter of 2024 is driven by its robust Surgical business. The performance of the Vision ...

Alcon said the Aerie deal is another example of its strategy to expand in the ophthalmic pharmaceutical eye drop space. "Aerie is a natural fit with on-market and pipeline products, and R&D ...

Moving to pharmaceutical eye drops, I’m pleased to announce that we recently finalized our strategic arrangement with OcuMension Therapeutics in China. Like Alcon, OcuMension is singularly ...

Though there are abundant home remedies that could help reduce the redness, the use of eye drops may offer instant relief and diminish eye swelling. When it comes to choosing the best eye drops ...

Novartis’ long-awaited separation from its eye care division Alcon completed on schedule today, allowing it to focus its energies on medicinal products. Alcon’s shares made their debut on the ...

Alcon, Inc. engages in the development, manufacture, and marketing of market surgical equipment and devices, pharmaceutical eye drops, and consumer vision care products to treat eye diseases and ...

In addition, Alcon plans to launch Systane Pro in the US in the first half of 2025. The SYSTANE Preservative-Free formula is effective for all types of dry eye. The new formula contains nanosized ...

GENEVA--(BUSINESS WIRE)--Alcon (SIX/NYSE: ALC), the global leader in eye care dedicated to helping people see brilliantly, today announced the U.S. launch of PRECISION7 ®, the only one-week ...

Alcon Inc (NYSE:ALC) is preparing for a series of product launches, including Precision7 contact lenses and Systane Pro Preservative Free eye drops, which are expected to drive future growth.